Magnet System, DI Biofragmentable

DEVICE6 trials

Sponsors

GT Metabolic Solutions, Inc.

Conditions

AnastomosisObesityType 2 DiabetesType 2 Diabetes Mellitus (T2DM)

Unknown Phase

Magnetic Jejuno-Ileal Diversion Study (MJI Study)

CompletedNCT06232746

GT Metabolic Solutions, Inc.Obesity, Type 2 Diabetes

Start: 2024-02-13End: 2025-06-24Updated: 2025-12-23

MagDI Canada Study

Active, not recruitingNCT06467955

GT Metabolic Solutions, Inc.Obesity, Type 2 Diabetes

Start: 2024-05-10End: 2026-11-01Target: 60Updated: 2026-05-20

MagDI Australia Study

CompletedNCT06473831

GT Metabolic Solutions, Inc.Obesity, Type 2 Diabetes

Start: 2024-08-13End: 2026-06-25Updated: 2026-09-11

Magnetic Duodeno-Ileal Chile Study

CompletedNCT06613724

GT Metabolic Solutions, Inc.Obesity, Type 2 Diabetes Mellitus (T2DM)

Start: 2024-10-14End: 2025-12-04Updated: 2025-12-26

MagDI Italian Study

CompletedNCT06613711

GT Metabolic Solutions, Inc.Anastomosis, Obesity, Type 2 Diabetes Mellitus (T2DM)

Start: 2024-09-20End: 2026-02-24Updated: 2026-05-20

Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System in Mexico

CompletedNCT07085741

GT Metabolic Solutions, Inc.Obesity, Type 2 Diabetes

Start: 2025-05-07End: 2026-06-21Updated: 2026-09-11